Stigma associated with cutaneous and mucocutaneous leishmaniasis: A systematic review (2023)
Journal Article
Nuwangi, H., Agampodi, T. C., Price, H. P., Shepherd, T., Weerakoon, K., & Agampodi, S. (in press). Stigma associated with cutaneous and mucocutaneous leishmaniasis: A systematic review. PLoS Neglected Tropical Diseases, 17(12), Article e0011818. https://doi.org/10.1371/journal.pntd.0011818

Background
Cutaneous (CL) and mucocutaneous leishmaniasis (MCL) are parasitic diseases caused by parasites of the genus leishmania leading to stigma caused by disfigurations. This study aimed to systematically review the dimensions, measurement meth... Read More about Stigma associated with cutaneous and mucocutaneous leishmaniasis: A systematic review.

Examining the Trends in Online Health Information–Seeking Behavior About Chronic Obstructive Pulmonary Disease in Singapore: Analysis of Data From Google Trends and the Global Burden of Disease Study (2021)
Journal Article
Fang, Y., Shepherd, T. A., & E Smith, H. (2021). Examining the Trends in Online Health Information–Seeking Behavior About Chronic Obstructive Pulmonary Disease in Singapore: Analysis of Data From Google Trends and the Global Burden of Disease Study. Journal of Medical Internet Research, 23(10), https://doi.org/10.2196/19307

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, and timely health care seeking is imperative for its prevention, early detection, and management. While online health information-seeking behavior... Read More about Examining the Trends in Online Health Information–Seeking Behavior About Chronic Obstructive Pulmonary Disease in Singapore: Analysis of Data From Google Trends and the Global Burden of Disease Study.

Supervised treatment in outpatients for schizophrenia plus (STOPS+): protocol for a cluster randomised trial of a community-based intervention to improve treatment adherence and reduce the treatment gap for schizophrenia in Pakistan (2020)
Journal Article
Shepherd, T. A., Ul-Haq, Z., Ul-Haq, M., Firaz Khan, M., Afridi, A., Dikomitis, L., …Farooq, S. (2020). Supervised treatment in outpatients for schizophrenia plus (STOPS+): protocol for a cluster randomised trial of a community-based intervention to improve treatment adherence and reduce the treatment gap for schizophrenia in Pakistan. BMJ Open, 10(6), https://doi.org/10.1136/bmjopen-2019-034709

Introduction: There is a significant treatment gap, with only a few community-based services for people with schizophrenia in Low- and Middle-Income countries. Poor treatment adherence in schizophrenia is associated with poorer health outcomes, suici... Read More about Supervised treatment in outpatients for schizophrenia plus (STOPS+): protocol for a cluster randomised trial of a community-based intervention to improve treatment adherence and reduce the treatment gap for schizophrenia in Pakistan.

Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairment (2017)
Journal Article
Shepherd, T. A., Edelstyn, N. M., Longshaw, L., Sim, J., Watts, K., Mayes, A. R., …Ellis, S. J. (2017). Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairment. Pilot and Feasibility Studies, https://doi.org/10.1186/s40814-017-0154-7

BACKGROUND: The aim was to assess the feasibility of a single-centre, single-blind, randomized, crossover design to explore the effects of two slow-release dopamine agonists, ropinirole and pramipexole, on cued recall in Parkinson's disease. As the d... Read More about Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairment.